Facebook
Twitter
LinkedIn
Forward
2020 ABAI Continuous Assessment Program Online Literature Review
This literature review course will help to prepare ABAI diplomates to participate in the Continuous Assessment Program (CAP). The course will include reviews of the journal articles selected for the 2020 term of the CAP to help develop greater familiarity with the key concepts included in them. This activity includes recordings of the Literature Review Course that was originally programmed for the 2020 AAAAI Annual Meeting.
The three presentations cover a range of clinical conditions central to the specialty, including:
- Mast Cell Disorders, Eosinophilic Disorders, Anaphylaxis, and Drug-Insect-Vaccine Allergy
- Asthma and Other Lung Disorders, Rhinosinusitis, Ocular Disorders and Allergy Testing and Therapeutics
- Food Allergy, Urticaria and Angioedema and other Allergic and Immunologic Skin Disorders
Click the Program tab to access the full list of articles, with links. Please note that All CAP articles can also be accessed through the ABAI web portal.
Target Audience
- Allergist/Immunologists participating in continuous certification with the American Board of Allergy & Immunology
- Allied health providers working in allergy/immunology settings
- Allergy/Immunology Fellows-in-Training preparing for initial certification
- Other healthcare providers with an interest in allergy/immunology
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate recently published research relevant to the practice of allergy/immunology
All CAP articles are listed, below.
Articles can also be accessed through the ABAI web portal, and via the following PDF document:
CAP 2020 - Block 1 Reference List - AAAAI.pdf
Articles for CAP 2020 – Block 1
A1 Head/Neck
• Jerschow E, et al. Sinus Surgery Is Associated with a Decrease in Aspirin-Induced Reaction Severity in Patients with Aspirin Exacerbated Respiratory Disease. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(5):1580-1588. https://www.sciencedirect.com/science/article/abs/pii/S2213219818308365?via=ihub.
• Leopold DA, et al. NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis. Journal of Allergy and Clinical Immunology. 2019;143(1):126-134.e5. https://www.jacionline.org/article/S0091-6749(18)30863-7/fulltext.
• Singh U, Wangia-Anderson V, Bernstein J. Chronic Rhinitis Is a High-Risk Comorbidity for 30-Day Hospital Readmission of Patients with Asthmaand Chronic Obstructive Pulmonary Disease. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(1):279-285.e6. https://www.sciencedirect.com/science/article/pii/S2213219818304483?via=ihub.
A2 Dermatologic
• Brar K, Nicol N, Boguniewicz M. Strategies for Successful Management of Severe Atopic Dermatitis. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(1):1-16. https://doi.org/10.1016/j.jaip.2018.10.021.
• Craig T, et al. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(6):1793-1802.e2. https://www.jaci-inpractice.org/article/S2213-2198(19)30163-1/pdf
• Milam EC, Jacob SE, Cohen DE. Contact Dermatitis in the Patient with Atopic Dermatitis. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(1):18-26. https://doi.org/10.1016/j.jaip.2018.11.003.
A3 Lung
• Beasley R, et al. Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma. The New England Journal of Medicine. 2019;380(21):2020-2030. https://www.nejm.org/doi/10.1056/NEJMoa1901963.
• Khatri S, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology. 2019;143(5):1742-1751.e7. https://www.jacionline.org/article/S0091-6749(18)31479-9/fulltext.
• Simmons R, et al. Case 16-2019: A 53-Year-Old Man with Cough and Eosinophilia. The New England Journal of Medicine. 2019;380(21):2052-2059. https://www.ncbi.nlm.nih.gov/pubmed/31116923
A4 Food and Drug Allergy/Hypersensitivity Reactions
• Dunlop J, et al. Long-Term Follow-Up After Baked Milk Introduction. Journal of Allergy and Clinical Immunology: In Practice. 2018;6(5):1699-1704. https://www.sciencedirect.com/science/article/abs/pii/S2213219818300515?via=ihub.
• Shenoy E, et al. Evaluation and Management of Penicillin Allergy A Review. The Journal of the American Medical Association. 2019;321(2):188-199. https://doi.org/10.1016/j.jaip.2018.01.024
• Venter C, Sicherer S, Greenhawt M. Management of Peanut Allergy. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(2):345-355.e2. https://doi.org/10.1016/j.jaip.2018.10.043.
A5 Anaphylaxis
• Golden D, Carter G. Insect Sting Anaphylaxis—Or Mastocytosis—Or Something Else? Journal of Allergy and Clinical Immunology: In Practice. 2019;(7):1117-1123. https://doi.org/10.1016/j.jaip.2019.01.014.
• Kennard L. A Multicenter Evaluation of Diagnosis and Management of Omega-5 Gliadin Allergy (Also Known as Wheat-Dependent Exercise-Induced Anaphylaxis) in 132 Adults. Journal of Allergy and Clinical Immunology: In Practice. 2018;6(6):1892-1897. https://doi.org/10.1016/j.jaip.2018.02.013.
• Shrestha P, et al. Trends in hospitalizations related to anaphylaxis, angioedema, and urticaria in the United States. Annals of Allergy, Asthma & Immunology. 2019;122(4):401-406.e2. https://doi.org/10.1016/j.anai.2019.02.003.
• Su J, et al. Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016. Journal of Allergy and Clinical Immunology. 2019;143(4):1465-1473. https://doi.org/10.1016/j.jaci.2018.12.1003.
B1 Immune Hypersensitivity Disorders
• Davis M, van der Hilst J. Mimickers of Urticaria: Urticarial Vasculitis and Autoinflammatory Diseases. Journal of Allergy and Clinical Immunology: In Practice. 2018;6(4):1162-1170. https://doi.org/10.1016/j.jaip.2018.05.006.
• June C, Sadelain M. Chimeric Antigen Receptor Therapy. The New England Journal of Medicine. 2018;379(1):64-73. https://www.nejm.org/doi/full/10.1056/NEJMra1706169.
• Montalban X, et al. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. The New England Journal of Medicine. June 2019:2406-2417. https://www.nejm.org/doi/10.1056/NEJMoa1901981.
B2 Immunodeficiencies
• Filion C, et al. Differentiation of Common Variable Immunodeficiency From IgG Deficiency. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(4):1277-1284. https://doi.org/10.1016/j.jaip.2018.12.004.
• Harris KM, et al. Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(3):809-818. https://doi.org/10.1016/j.jaip.2018.10.049.
• Scott O, Roifman C. NF-kB pathway and the Goldilocks principle: Lessons from human disorders of immunity and inflammation. Journal of Allergy and Clinical Immunology. 2019;143(5):1688-1701. https://doi.org/10.1016/j.jaci.2019.03.016.
B3 Eosinophilic or Gastrointestinal Disorders
• Burris D, et al. Pediatric Hypereosinophilia: Characteristics, Clinical Manifestations, and Diagnoses. Journal of Allergy and Clinical Immunology: In Practice. 2019. https://doi.org/10.1016/j.jaip.2019.05.011.
• Khoury P, Bochner B. Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options. Journal of Allergy and Clinical Immunology: In Practice. 2018;6(5):1446-1453. https://doi.org/10.1016/j.jaip.2018.04.030
• Kuang FL, et al. Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome. The New England Journal of Medicine. 2019;380(14):1336-1346. https://www.ncbi.nlm.nih.gov/pubmed/30943337
Planning Committee
See attachment at bottom of page for Annual Meeting Planning Committee disclosure information.
Faculty
Carla Davis, MD FAAAAI
Baylor College of Medicine, Houston, TX
Relevant relationships: None
Caroline Horner, MD FAAAAI
Washington University School of Medicine, St. Louis, MO
Relevant relationships: None
John Kelso, MD FAAAAI
Scripps Clinic, La Jolla, CA
Relevant relationships: None
COI Reviewers
Edwin Kim, MD MS FAAAAI
University of North Carolina, School of Medicine, Chapel Hill, NC
Relevant relationships: DBV Technologies, Aimmune: food allergy, oral immunotherapy
AAAAI Disclosure Policy
Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, authors and reviewers are required to disclose all relationships that meet the following parameters:
- Employment. Name of employer and job title.
- Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).
- Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.
- Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.
- Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
- Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.
- Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.
The information disclosed by the speakers and planning committee was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity.
Accreditation Statement
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAAAI Privacy Policy
To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at cme@aaaai.org.
Release date
Original release date: July, 24, 2020. Valid for credit through December 31, 2020.
Questions
Activity-related questions should be directed to cme@aaaai.org.
Available Credit
- 2.25 AttendanceAttendance credit.
- 2.25 CMECME credit.